FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
New schizophrenia drug could ‘change the lives of millions of people’
The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...
FDA Approves New Schizophrenia Drug in 70-Year First
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
Futures slip as investors await key inflation report
A Commerce Department report, due at 8:30 a.m. ET, is expected to show the Personal Consumption Expenditure Index - the Fed's ...
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava Sciences, Trump Media, HP Inc., and More
Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...
kffhealthnews41m
Antipsychotic Drug Cobenfy Wins FDA Approval For Schizophrenia Treatment
The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...
Fed’s preferred inflation gauge rose 2.2% last month
Data through the week points to a still-resilient economy overall, leaving traders uncertain about the Fed’s next move.
Dow Jones Today: Stock Futures Little Changed Ahead of Key Inflation Data
Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...
Managed Healthcare Executive56m
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
Why these two stock-market sectors need to be treated with caution
Jeffrey Rubin, the president and director of research at Westport, Conn.-based Birinyi Associates - who now owns the firm following the death of the legendary Laszlo Birinyi - is among those who is ...
FDA approves new kind of drug for schizophrenia
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...